HBM Holdings Limited (FRA:6XY)

Market Cap	1.29B -9.4%
Revenue (ttm)	156.81M +54.8%
Net Income	73.96M +15.6%
EPS	0.09 +11.2%
Shares Out	n/a
PE Ratio	17.43
Forward PE	17.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.520
Previous Close	1.370
Day's Range	1.520 - 1.530
52-Week Range	1.030 - 1.800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About HBM Holdings

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for tr...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 327
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6XY

Financial Performance

In 2025, HBM Holdings's revenue was $157.98 million, an increase of 314.63% compared to the previous year's $38.10 million. Earnings were $91.33 million, an increase of 3187.72%.

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 19, 2026

Data Sources Report a data error